Meditope Biosciences, Inc. is an early stage biotechnology company developing the next generation of immuno-oncology products by leveraging its revolutionary, LEGO-like "SnAP" technology (Site-specific novel Antibody Platform). The power and simplicity of SnAP allows for a broad range of molecules – proteins, other antibodies / antibody fragments, toxins, radiolabels – to be "snapped" on or off of an antibody, with predictability, precision and control. As a result, a vast array of immuno-oncology products can be constructed with ease and efficiency, including 'switchable' CAR-Ts, novel bispecifics/trispecific molecules, antibody-protein conjugates, etc.
For more information, contact:
Meditope Biosciences, Inc.
177 E. Colorado Blvd., Suite 200
Pasadena, CA 91105